Shenzhen Shankang Pharmaceutical Technology Co., Ltd. was established in October 2017 and is a modern pharmaceutical enterprise invested by multiple funds including Shenzhen Venture Capital, Xiaoxiang Capital, Guojin Fund, and People's Daily Online. There is a drug research institute and industrialization base in Pingshan District, Shenzhen, which has mastered the core sustained-release technology and materials of long-acting drugs. The research and development pipeline focuses on the fields of drug rehabilitation and psychiatry, and the main varieties cover the ecology of drug rehabilitation. It is a leading enterprise in the field of drug rehabilitation in China. The main product, the anti opioid relapse drug "naltrexone hydrochloride implant", was approved by the State Food and Drug Administration for listing in China in June 2024. It is a major innovative achievement in the field of drug rehabilitation drugs independently developed.